No Data
No Data
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Business And Shares Still Trailing The Industry
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
Baird Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Optimistic Buy Rating for Sarepta Therapeutics Amid Strong International Demand and Collaborative Potential
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
S&P 500 Futures Fall In Premarket Trading; Range Resources, Mueller Industries Lead